Delphine Leclerc

Delphine Leclerc

Auto-generated profile, based on publicly available information

Delphine Leclerc

INSERM

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Vaccine
Verified
Journal Article
Closed access
CGCatherine Goujon
Catherine Goujon
MGMarie-Lise W Gougeon
Marie-Lise W Gougeon
LTLaura Tondeur
Laura Tondeur
BPBéatrice Poirier
Béatrice Poirier
VSValérie Seffer
Valérie Seffer
BWBenjamin Wyplosz
Benjamin Wyplosz

5 September 2023 in JHEP Reports
Verified
Journal Article
Open access
CLCorentin Louis
Corentin Louis
TFTanguy Ferlier
Tanguy Ferlier
RLRaffaële Leroux
Raffaële Leroux
RPRaphaël Pineau
Raphaël Pineau
Matthis DesoteuxMatthis Desoteux
Matthis Desoteux
Cedric CoulouarnCedric Coulouarn
Cedric Coulouarn
Intrahepatic cholangiocarcinoma (iCCA) is a deadly cancer worldwide with an increasing incidence and limited therapeutic options. Therefore, there is an urgent need to open the field to new concepts for identifying clinically relevant therapeutic targets and biomarkers. Here, we explored the role and the clinical relevance of circular RNA (circRNA) circLTBP2 in iCCA. Transforming growth factor β (TGFβ)-regulated circRNAs were identified by dedicated microarrays in human HuCC-T1 iCCA cell line, and their clinical relevance was evaluated in independent cohorts of patients. Gain and loss of function of circLTBP2 combined with functional tests was performed in vitro and in vivo in mice. RNA pulldown, microRNA sequencing, and RNA immunoprecipitation were performed to explore the sponging activity of circLTBP2. CircLTBP2 (has_circ_0032603) was identified as a novel TGFβ-induced circRNA in several cholangiocarcinoma cell lines. CircLTBP2 promotes tumour cell proliferation, migration, and resistance to gemcitabine-induced apoptosis in vitro and tumour growth in vivo. Mechanistically, circLTBP2 acts as a competitive RNA regulating notably the activity of the tumour suppressor microRNA miR-338-3p, leading to the overexpression of its pro-metastatic targets. The restoration of miR-338-3p levels in iCCA cells reversed the pro-tumourigenic effects driven by circLTBP2, including the resistance to gemcitabine-induced apoptosis. In addition, circLTBP2 expression predicted a reduced survival, as detected in not only tumour tissues but also serum extracellular vesicles isolated from patients with iCCA. CircLTBP2 is a novel effector of the pro-tumourigenic arm of TGFβ and a clinically relevant biomarker easily detected from liquid biopsies in iCCA. Intrahepatic cholangiocarcinoma (iCCA) is an aggressive cancer with limited therapeutic options. Opening the field to new concepts is urgently needed to improve the survival of patients. Here, we evaluated the role and the clinical relevance of circular RNA. We report that TGFβ-induced circLTBP2 contributes to CCA carcinogenesis and may constitute a clinically relevant prognostic biomarker detected in liquid biopsies.

1 June 2016 in Medecine Et Maladies Infectieuses
Verified
Journal Article
Closed access
MGM. Gousseff
M. Gousseff
AMA. Messager
A. Messager
NVNicolas Vignier
Nicolas Vignier
BIB. Issartel
B. Issartel
FSF. Suy
F. Suy
PTP. Tattevin
P. Tattevin

7 April 2026
Verified
Thesis
Closed access
DLDelphine Leclerc
Delphine Leclerc
Ces dernières années, de considérables progrès ont été obtenus en médecine génomique. L’apport de la technologie de séquençage haut-débit dans les laboratoires de génétique médicale a notamment permis de mieux diagnostiquer les pathologies génétiques rares. Malgré cette avancée, un nombre important de patients diagnostiqués se retrouvent en errance thérapeutique. Environ 250 millions de personnes souffrent de pathologies génétiques rares et moins de 5% de ces pathologies disposent aujourd’hui de traitements efficaces. La découverte et l’amélioration constante des outils CRISPR/Cas9 ont ouvert la porte à une nouvelle médecine, la chirurgie du génome. Dans ce contexte, une partie importante des altérations génétiques responsables de maladies rares peuvent être en théorie directement corrigées par cette approche, ouvrant une perspective thérapeutique inespérée pour des patients étant parfois les seuls porteurs de ces altérations génétiques. Au cours de ma thèse, j’ai l’opportunité de développer et d’évaluer les outils d’édition du génome CRISPR/Cas9, d’une part pour concevoir et mesurer l’efficacité de nouveaux traitement in vitro, et d’autre part pour installer et décrypter le rôle biologique de variants génétiques de signification inconnue. Désormais, il est possible de corriger ou créer ces variants en recherche fondamentale afin d’aider les cliniciens à conclure sur leur rôle biologique ouvrant la porte à des thérapies personnalisées dans un futur proche.

29 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
PGPaola Galbiati
Paola Galbiati
DLDelphine Leclerc
Delphine Leclerc
MMMargaux Mombled
Margaux Mombled
RKRuqayya Khan
Ruqayya Khan
MRMaelle Ralu
Maelle Ralu
MAMario Amendola
Mario Amendola
Duchenne muscular dystrophy is a lethal neuromuscular disorder caused by the absence of dystrophin, for which no curative treatment is available. RNA based approaches have shown promising results; however, their evaluation is hindered by the lack of robust and rapid delivery methods for differentiated human muscle cells, which represent the most physiologically relevant in vitro models for assessing therapeutic strategies. Here, we establish a versatile lipid nanoparticle platform enabling efficient delivery of diverse RNA therapeutics across a range of human muscle models, including myotubes, induced pluripotent stem cell-derived myotubes, myoblasts, cardiomyocytes, and 3D engineered skeletal muscle tissues. Remarkably, a single commercially available lipid nanoparticle formulation supports delivery of cargos spanning more than 300-fold in size, from short antisense oligonucleotides (~20 nt) to complex CRISPR-based editors (up to ~6.7 kb), including Cas9 nucleases, adenine base editors, and CRISPRa systems. This enables efficient gene correction and transcriptional modulation, resulting in dystrophin restoration or compensatory utrophin upregulation in relevant Duchenne muscular dystrophy models. Together, our results establish a single lipid nanoparticle formulation as a versatile platform for RNA delivery in human muscle systems and provide a practical framework for the rapid preclinical assessment of emerging therapies for Duchenne muscular dystrophy and other neuromuscular disorders.

1 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
AQAnaïs M. Quéméner
Anaïs M. Quéméner
LBLaura Bachelot
Laura Bachelot
MAMarc Aubry
Marc Aubry
SAStéphane Avner
Stéphane Avner
DLDelphine Leclerc
Delphine Leclerc
David GilotDavid Gilot
David Gilot
Uveal melanoma (UM), the most common primary intraocular tumor in adults, has been extensively characterized by omics technologies during the last 5 years. Despite the discovery of gene signatures, the molecular actors driving the cancer aggressiveness are not fully understood and UM is still associated to a dismal overall survival at metastatic stage. Here, we showed that microRNA-16 (miR-16) is involved in uveal melanoma by an unexpected mechanism. By defining the miR-16-interactome, we revealed that miR-16 mainly interacts via non-canonical base-pairing to a subset of RNAs, promoting their expression levels (sponge RNAs). Consequently, the canonical miR-16 activity, involved in the RNA decay of oncogenes such as cyclin D1 and D3, is impaired. This miR-16 non-canonical base-pairing to sponge RNAs can explain both the derepression of miR-16 targets and the promotion of oncogenes expression observed for patients with poor overall survival in two cohorts. miR-16 activity assessment using our sponge-signature discriminates the patient’s overall survival as efficiently as the current method based on copy number variations and driver mutations detection. To conclude, miRNA loss of function due to miRNA sequestration seems to promote cancer burden by two combined events – “loss of brake and an acceleration”. Our results highlight the oncogenic role of the non-canonical base-pairing between miRNAs/mRNAs in uveal melanoma.